CTOs on the Move

Covance

www.covance.com

 
As the drug development business of Laboratory Corporation of America Holdings (LabCorp) and the world’s most comprehensive drug development service company, we have helped pharmaceutical and biotech companies develop 100% of the top 50 prescription drugs in the marketplace today. Because of our broad experience and specialized expertise, we’re in a unique position to supply insights that go above and beyond testing. Together with our clients, we create solutions that transform potential into reality.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.covance.com
  • 210 Carnegie Center
    Princeton, NJ USA 08540
  • Phone: 609.452.4440

Executives

Name Title Contact Details

Similar Companies

Omnibus Health

Omnibus Health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MGC Diagnostics Corporation

MGC Diagnostics Corporation is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carolinas Shared Services

Carolinas Shared Services is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Essentia Health

Essentia Health is an integrated health system serving patients in Minnesota, North Dakota, Wisconsin and Idaho. In the summer of 2010, Essentia Health brought together the operations of SMDC Health System, Brainerd Lakes Health, Innovis Health, Essentia Community Hospitals and Clinics, and the Essentia Institute of Rural Health. Essentia Health was originally formed in January 2004 through a partnership of the Benedictine Health System and SMDC Health System. In January 2008, Innovis Health joined Essentia Health and all of the hospitals and clinics owned by the Benedictine Health System were transferred to Essentia Community Hospitals and Clinics.

Wave Life Sciences

WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.